$1.17 Billion in Sales Expected for Xylem Inc. (NYSE:XYL) This Quarter


Share on StockTwits

Brokerages forecast that Xylem Inc. (NYSE:XYL) will post $1.17 billion in sales for the current quarter, Zacks reports. Five analysts have made estimates for Xylem’s earnings, with the lowest sales estimate coming in at $1.16 billion and the highest estimate coming in at $1.21 billion. Xylem posted sales of $1.12 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 4.5%. The firm is scheduled to announce its next quarterly earnings results before the market opens on Tuesday, May 4th.

According to Zacks, analysts expect that Xylem will report full year sales of $5.19 billion for the current financial year, with estimates ranging from $5.09 billion to $5.25 billion. For the next fiscal year, analysts anticipate that the company will report sales of $5.48 billion, with estimates ranging from $5.35 billion to $5.61 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Xylem.

Xylem (NYSE:XYL) last announced its quarterly earnings results on Thursday, February 4th. The industrial products company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.13. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.29 billion. Xylem had a net margin of 5.09% and a return on equity of 14.72%. The company’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.34 earnings per share.

Several equities research analysts have recently issued reports on the stock. Credit Suisse Group increased their price objective on shares of Xylem from $89.00 to $90.00 and gave the stock an “underperform” rating in a research report on Friday, February 5th. Citigroup lowered their price target on shares of Xylem from $113.00 to $109.00 and set a “neutral” rating for the company in a report on Friday, February 5th. Morgan Stanley assumed coverage on shares of Xylem in a report on Wednesday, March 31st. They set an “overweight” rating and a $120.00 price target for the company. Cowen lowered shares of Xylem from a “market perform” rating to an “underperform” rating and set a $65.00 price target for the company. in a report on Friday, January 8th. Finally, Raymond James lowered shares of Xylem from an “outperform” rating to a “market perform” rating in a report on Friday, January 8th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $87.50.

In other Xylem news, SVP Hayati Yarkadas sold 6,447 shares of Xylem stock in a transaction dated Monday, March 29th. The stock was sold at an average price of $104.28, for a total value of $672,293.16. Following the transaction, the senior vice president now owns 15,503 shares in the company, valued at $1,616,652.84. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Claudia S. Toussaint sold 5,948 shares of Xylem stock in a transaction dated Tuesday, March 16th. The shares were sold at an average price of $102.75, for a total value of $611,157.00. Following the sale, the senior vice president now directly owns 59,057 shares in the company, valued at $6,068,106.75. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,744 shares of company stock valued at $1,963,307. 1.01% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XYL. Exchange Traded Concepts LLC bought a new stake in shares of Xylem during the fourth quarter valued at approximately $26,000. Syverson Strege & Co purchased a new stake in Xylem in the 4th quarter worth approximately $30,000. Crescent Capital Consulting LLC bought a new position in Xylem during the 4th quarter valued at approximately $31,000. Bainco International Investors bought a new stake in shares of Xylem in the 4th quarter worth $33,000. Finally, Wealthcare Advisory Partners LLC bought a new stake in shares of Xylem in the first quarter worth $40,000. Hedge funds and other institutional investors own 84.92% of the company’s stock.

NYSE:XYL opened at $111.60 on Tuesday. Xylem has a fifty-two week low of $56.63 and a fifty-two week high of $112.64. The firm’s 50 day moving average is $106.62 and its two-hundred day moving average is $100.16. The company has a market cap of $20.13 billion, a P/E ratio of 80.29, a P/E/G ratio of 4.89 and a beta of 1.05. The company has a quick ratio of 1.97, a current ratio of 2.40 and a debt-to-equity ratio of 1.06.

The business also recently declared a quarterly dividend, which was paid on Thursday, March 18th. Investors of record on Thursday, February 18th were issued a dividend of $0.28 per share. This is a boost from Xylem’s previous quarterly dividend of $0.26. This represents a $1.12 annualized dividend and a dividend yield of 1.00%. The ex-dividend date of this dividend was Wednesday, February 17th. Xylem’s dividend payout ratio (DPR) is currently 37.09%.

About Xylem

Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions for the water and wastewater applications in the United States, Europe, the Asia Pacific, and internationally. It operates in three segments: Water Infrastructure, Applied Water, and Measurement & Control Solutions.

Featured Article: What is Compound Interest?

Get a free copy of the Zacks research report on Xylem (XYL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xylem (NYSE:XYL)

Receive News & Ratings for Xylem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xylem and related companies with MarketBeat.com's FREE daily email newsletter.